Baird raised the firm’s price target on Vor Bio (VOR) to $1 from 25c and keeps a Neutral rating on the shares. The firm updated its model following the licensing of Telitacicept from RemGen for autoimmune diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: